RBC Capital defends Karyopharm Therapeutics (KPTI) amid 10pct premarket drop: 'We see upside potential'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $23.00 price target on Karyopharm ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
